Details of the Drug

General Information of Drug (ID: DMNER5S)

• Drug Name: Bleomycin
• Synonyms: BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Approved	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 5:
  Molecular Weight (mw); 1415.6
  Topological Polar Surface Area (xlogp); -7.5
  Rotatable Bond Count (rotbonds); 36
  Hydrogen Bond Donor Count (hbonddonor); 20
  Hydrogen Bond Acceptor Count (hbondacc); 31
• ADMET Property:
  Absorption: The systemic absorption of drug is approximately 45% [2]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.26 mL/min/kg [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 115 minutes [3]
  Metabolism: The drug is metabolized via the hepatic [2]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3532 micromolar/kg/day [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.43 L/kg [3]
• Chemical Identifiers:
  Formula: C55H84N17O21S3+
  IUPAC Name: 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
  Canonical SMILES: CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
  InChI: InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
  InChIKey: OYVAGSVQBOHSSS-WXFSZRTFSA-O
• Cross-matching ID:
  PubChem CID: 5360373
  CAS Number: 11056-06-7
  DrugBank ID: DB00290
  TTD ID: D06UVD
  VARIDT ID: DR00409
  INTEDE ID: DR0217

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Bleomycin hydrolase (BLMH) Main DME	DECH1VP	BLMH_HUMAN	Substrate	[6]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bleomycin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Roflumilast.	Asthma [CA23]	[17]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[18]
Ceftazidime	DM41GRA	Moderate	Increased risk of nephrotoxicity by the combination of Bleomycin and Ceftazidime.	Bacterial infection [1A00-1C4Z]	[19]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
ABT-492	DMJFD2I	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[18]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[18]
Digoxin	DMQCTIH	Moderate	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Digoxin.	Heart failure [BD10-BD1Z]	[20]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Bleomycin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[21]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Bleomycin and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[19]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Denosumab.	Low bone mass disorder [FB83]	[22]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Bleomycin and Thalidomide.	Multiple myeloma [2A83]	[23]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Tecfidera.	Multiple sclerosis [8A40]	[24]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Bleomycin and Siponimod.	Multiple sclerosis [8A40]	[19]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Bleomycin and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Ocrelizumab.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Bleomycin and Ozanimod.	Multiple sclerosis [8A40]	[17]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[27]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[18]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Canakinumab.	Rheumatoid arthritis [FA20]	[28]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Rilonacept.	Rheumatoid arthritis [FA20]	[28]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Bleomycin and Golimumab.	Rheumatoid arthritis [FA20]	[29]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Bleomycin and Leflunomide.	Rheumatoid arthritis [FA20]	[21]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Bleomycin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[30]
Etoposide	DMNH3PG	Moderate	Additive myelosuppressive effects by the combination of Bleomycin and Etoposide.	Solid tumour/cancer [2A00-2F9Z]	[31]
Cisplatin	DMRHGI9	Moderate	Increased risk of nephrotoxicity by the combination of Bleomycin and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Bleomycin and Azathioprine.	Transplant rejection [NE84]	[19]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[18]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Bleomycin and Plazomicin.	Urinary tract infection [GC08]	[19]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[18]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Bleomycin due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[18]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Bleomycin and Ganciclovir.	Virus infection [1A24-1D9Z]	[19]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Bleomycin and Valganciclovir.	Virus infection [1A24-1D9Z]	[19]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
• [6] The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998 Oct 12;421(1):1-7.
• [7] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [8] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [9] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [10] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [11] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [12] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [13] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [14] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [15] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [16] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
• [17] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [18] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R "Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations." Clin Pharmacol Ther 39 (1986): 25-8. [PMID: 3943266]
• [21] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [22] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [23] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [24] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [25] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [26] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [27] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [28] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [29] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [30] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [31] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".